Longevity & Senolytic Patents

Longevity and senolytic patents cover senolytic and senomorphic innovations; cellular/partial-reprogramming innovations; metabolic and NAD-pathway innovations; and aging-biomarker innovations — with IP held by senolytic developers, well-funded reprogramming companies, and aging-research firms (in a field with a recurring IP challenge: many candidate molecules are REPURPOSED existing drugs, hence prior art). MAJOR LONGEVITY PATENT HOLDERS: UNITY BIOTECHNOLOGY: SENOLYTICS — drugs that selectively kill senescent ('zombie') cells (which accumulate with age and drive inflammation/dysfunction) — UBX programs (e.g. local Bcl-xL-inhibitor senolytics for eye/joint disease). ALTOS LABS: cellular/partial REPROGRAMMING (resetting cells toward a younger state) — a very-well-funded ($3B) effort with leading scientists (Belmonte, Izpisua Belmonte). LIFE BIOSCIENCES: partial reprogramming via transient OSK (Oct4/Sox2/Klf4) factors to restore youthful gene expression without changing cell identity (David Sinclair's approach). OTHERS: Calico Life Sciences (Alphabet/Google — aging biology), Retro Biosciences (reprogramming/autophagy), Rubedo Life Sciences and Cleara (senolytics), BioAge Labs (metabolic aging — apelin/NLRP3), Gero, Loyal (dog longevity), and academic founders (the Mayo Clinic senescence work, the Sinclair/Belmonte reprogramming work). Senolytics, partial reprogramming, senomorphics, and aging biomarkers are the core longevity patent domains — and the repurposed-drug prior-art problem shapes strategy (much like psychedelics).

Senolytic-drug innovations; senescent-cell-targeting innovations; senomorphic (SASP-suppressing) innovations; and prodrug/delivery innovations represent core longevity patent domains — though many lead senolytics are repurposed drugs (prior art), so novel composition or targeted delivery is needed for durable IP. SENOLYTIC PATENTS: drugs that selectively kill senescent cells by exploiting their dependence on anti-apoptotic 'SCAP' survival pathways — Bcl-2/Bcl-xL inhibitors (navitoclax and derivatives), dasatinib + quercetin (the classic 'D+Q' combo — but these are REPURPOSED existing drugs, hence prior art as compositions, so the IP must be in NEW senolytics, specific combinations, or formulations), FOXO4-DRI peptides, fisetin, and NOVEL senolytic chemotypes (composition-of-matter for a new molecule is the durable IP). TARGETED-SENOLYTIC / PRODRUG PATENTS: targeting senolytics specifically to senescent cells (senescence-activated prodrugs cleaved by senescence-associated β-galactosidase, antibody/nanoparticle targeting) — improving the therapeutic window and avoiding killing healthy cells, a high-value, patentable approach. SENOMORPHIC PATENTS: drugs that don't kill senescent cells but SUPPRESS their harmful senescence-associated secretory phenotype SASP (inflammatory secretions) — JAK inhibitors, NF-κB/NLRP3 modulators. MECHANISM PATENTS: targeting specific senescence/aging pathways. Novel senolytic chemotypes (composition-of-matter) and senescence-targeted prodrugs (improving selectivity) are the highest-value senolytic IP — because the famous senolytics are repurposed and prior-art-constrained.

Cellular/partial-reprogramming innovations; reprogramming-factor and delivery innovations; NAD-pathway and metabolic innovations; and epigenetic-clock/biomarker innovations represent additional longevity patent domains — and partial reprogramming is the most novel, defensible longevity science. PARTIAL-REPROGRAMMING PATENTS: transiently expressing Yamanaka/reprogramming factors (especially OSK — Oct4/Sox2/Klf4, omitting Myc) to reset a cell's epigenetic 'age' (restoring youthful gene expression and function) WITHOUT dedifferentiating it to a stem cell or causing tumors — the safety-critical, patentable challenge is controlling the dose/duration/specificity so cells get younger but keep their identity; factor selection (OSK vs OSKM vs chemical reprogramming), delivery (AAV with inducible expression, mRNA/LNP, small-molecule reprogramming), and tissue-specific/inducible control are key, high-value claims (Altos, Life Bio, and the Sinclair/Belmonte foundational reprogramming patents). CHEMICAL-REPROGRAMMING PATENTS: small-molecule cocktails that reprogram without genetic factors (safer delivery). NAD / METABOLIC PATENTS: NAD+ boosters (NMN, NR — but many are supplements/prior art), NAD-pathway enzymes (sirtuins, NAMPT), and metabolic-aging targets — novel compounds vs prior-art supplements. AGING-BIOMARKER PATENTS: epigenetic 'clocks' (DNA-methylation-based biological-age measures — Horvath clocks) and other aging biomarkers used to measure intervention effect — these measurement methods face §101 (a bare 'measure age from methylation' claim is vulnerable) and are best tied to a specific assay or kept as trade secrets. Partial reprogramming (especially safe, controlled, deliverable) and novel senolytics are the highest-value longevity IP because they are genuinely new science, not repurposed compounds.

Longevity startup IP strategy must navigate the REPURPOSED-DRUG prior-art problem (many candidate senolytics, NAD boosters, and metabolic agents are existing drugs/supplements — unpatentable as compositions), the foundational reprogramming patents (Yamanaka/iPSC, Sinclair/Belmonte partial reprogramming — license/FTO), §101 limits on aging-biomarker methods, the long/uncertain regulatory path (aging is not an FDA-recognized 'disease' — trials target specific age-related diseases, e.g. TAME/metformin), and a landscape where genuinely novel molecules and reprogramming methods are the durable assets; understand that you generally cannot patent a repurposed drug as a composition, so the durable IP is in NOVEL senolytic chemotypes, senescence-targeted prodrugs, controlled/safe partial-reprogramming methods, and chemical reprogramming, and that the regulatory path and demonstrated efficacy matter as much as patents; identify whitespace in novel senolytics, targeted prodrugs, safe partial reprogramming, and chemical reprogramming. LONGEVITY STARTUP IP STRATEGY: REPURPOSED DRUGS ARE PRIOR ART — NOVEL MOLECULES AND REPROGRAMMING METHODS ARE THE IP: D+Q, navitoclax, NMN/NR, rapamycin, and metformin are existing drugs/supplements (prior art) — patent NOVEL senolytic chemotypes (composition-of-matter), senescence-targeted prodrugs, and controlled partial-reprogramming methods, not repurposed compounds; PARTIAL REPROGRAMMING IS THE HIGHEST-VALUE, MOST-NOVEL WHITESPACE — BUT CONTROL IS THE PATENTABLE CHALLENGE: safe, dose/duration/tissue-controlled OSK (or chemical) reprogramming that rejuvenates cells without tumorigenesis or identity loss is the defining science and IP — but license the Yamanaka/Sinclair foundational FTO; NOVEL AND TARGETED SENOLYTICS ARE DURABLE: a new senolytic chemotype or a senescence-activated prodrug (improving the therapeutic window over toxic broad senolytics) is composition/method IP; CHEMICAL REPROGRAMMING AND DELIVERY ARE OPEN: small-molecule reprogramming (no genes) and safe deliverable systems (inducible AAV, mRNA/LNP) are valuable; AGING BIOMARKERS ARE §101-SENSITIVE: epigenetic clocks (a bare 'measure age' claim) are abstract-idea-vulnerable — tie to a specific assay or keep as trade secret; THE REGULATORY PATH IS EXISTENTIAL: aging isn't an FDA disease indication — target specific age-related diseases; trial design and efficacy matter as much as IP; WHEN TO PATENT: NOVEL MOLECULE/METHOD WITH MEASURED EFFECT: file once a novel senolytic/reprogramming method shows measured results (senescent-cell clearance/selectivity, or epigenetic-age reduction + function restoration + safety) — for genuinely novel matter, measured efficacy, selectivity, and safety are the critical longevity IP metrics; KEY FTO CHECKLIST: Unity Bcl-xL/Bcl-2 senolytic (navitoclax repurposed — novel chemotype needed); D+Q dasatinib+quercetin/fisetin/FOXO4-DRI (repurposed prior art); senescence-activated prodrug β-galactosidase-cleaved targeted; senomorphic JAK/NF-κB/NLRP3 SASP; Altos/Life Bio/Sinclair-Belmonte OSK partial reprogramming (license + controlled-dose/safety IP); chemical reprogramming small-molecule; Yamanaka/iPSC reprogramming FTO; NAD NMN/NR (supplement prior art); epigenetic-clock biomarker (§101-tied/trade-secret); aging-not-an-FDA-disease regulatory path.